Macquarie cuts PT, downgrades rating for Australia's CSL on weaker outlook

Csl

14/12/2025 22:50

** Macquarie cuts PT for Australia's CSL CSL.AX to A$188 from A$275 and downgrades stock to "neutral" from "outperform"

** Trims EPS estimates for biotech firm by 4%, 5% and 5% for FY26, FY27 and FY28 respectively, reflecting downgraded guidance due to softer performance at Seqirus, among others

**  Sees risk to co's FY26 guidance with 2H reliant on containing China's albumin impacts

** Estimates 25% of CSL Behring's immunoglobulin share in Chronic Inflammatory Demyelinating Polyneuropathy is at risk, which could result in a 4% EPS impact by FY33.

** Average rating of 16 analysts is "buy"; their median PT is A$237 – according to data compiled by LSEG

** Stock down 34.7% YTD

 (Reporting by Sneha Kumar in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))